Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory Developments On Pharmaceutical Intellectual Property Rights

This article was originally published in PharmAsia News

Executive Summary

China Intellectual Property News published an article introducing the laws and regulations on intellectual property rights for pharmaceuticals. Related laws cover patent, trademark, drug administration and anti-trust competition. Reviews are provided on regulatory provisions for new drugs approvals, protection of new medicines and technology transfer, administrative protection of pharmaceuticals, drug registration, and protection of TCM. The overview summarized the protection of pharmaceuticals from different aspects-protection terms, major content and newly revised items after China's entry to the World Trade Organization. Last year, the country ratified an amended version of WTO's Agreement of the Trade-Related Aspects of Intellectual Property Rights, which attempts to strike a balance between IPRs and public health. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel